



16538

TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
DI-4389 US DIV

In Re Application of: **Martis et al.**

Serial No.
09/909,733

Filing Date
July 20, 2001

Examiner
Lukton

Group Art Unit
1653

Title: **IMPROVED PERITONEAL DIALYSIS SOLUTIONS WITH POLYPEPTIDES**

RECEIVED

JUL 08 2002

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

TECH CENTER 1600/2900

Transmitted herewith is:

Response to Office Action, Transmittal of Information Disclosure Statement in duplicate, Supplemental Information Disclosure Statement, PTO 1449, references, fee \$180.00, postcard

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **02-1818** as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of **\$180.00**
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Dated: **June 20, 2002**

Signature

Robert M. Barrett (Reg. No. 30,142)
Bell, Boyd & Lloyd LLC
P.O. Box 1135
Chicago, Illinois 60690

I certify that this document and fee is being deposited on **June 20, 2002** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Signature of Person Mailing Correspondence

Robert Buccieri

Typed or Printed Name of Person Mailing Correspondence

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Martis et al.
Appl. No.: 09/909,733
Filed: July 20, 2001
Title: Improved Peritoneal Dialysis Solutions with Polypeptides
Art Unit: 1653
Examiner: D. Lukton
Docket No.: DI-4389 US DIV

RECEIVED

JUL 08 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231

RESPONSE TO OFFICE ACTION

Sir:

In response to the Office Action dated March 22, 2002, please amend the above-identified patent application as follows:

In the Claims:

Please amend Claim 2 as follows:

2. (Amended) A two part peritoneal dialysis solution designed to be mixed prior to infusion into a patient comprising:

a first part housed in a first structure, the first part including approximately 1.0 to about 8% (w/v) dextrose and a pH of approximately 4.0 to about 5.5;

a second part housed in a second structure, the second part including approximately 0.5 to about 8.0% (w/v) polypeptides and a pH of approximately 6.0 to about 7.5; and

including in either the first or the second structure a sufficient amount of the following ingredients so when the first part and second part are mixed, the following is provided: 120 to about 150 (mEq/L) sodium; 80.0 to about 110.0 (mEq/L) chloride; 0.0 to about 5.0 (mEq/L) lactate; 0.0 to about 45.0 (mEq/L) bicarbonate; 0.0 to about 4.0 (mEq/L) calcium; and 0.0 to about 4.0 (mEq/L) magnesium.